Basilea buys Spexis’ preclinical antibiotics programme for $2.3m

The acquired programme consists of antibiotics against gram-negative bacteria, including multidrug-resistant strains.

Jan 15, 2024 - 18:00

Basilea buys Spexis’ preclinical antibiotics programme for $2.3m

The acquired programme consists of antibiotics against gram-negative bacteria, including multidrug-resistant strains.

Read the original article

Tags:

Previous Article

MSD’s Keytruda wins expanded FDA combo approval in cervical cancer

PCM Trials acquires Netherlands-based Clinical Trial Service, becoming the most ...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Opinion: AI can’t replicate this key part of practicing medicine

Opinion: AI can’t replicate this key part of practicing...

Jul 18, 2023

STAT+: AbbVie sues a behind-the-scenes company for exploiting its patient assistance program

STAT+: AbbVie sues a behind-the-scenes company for expl...

May 11, 2023

Opinion: Opportunistic CT: There’s gold in them there images

Opinion: Opportunistic CT: There’s gold in them there i...

May 25, 2023